The global oral controlled release drug delivery technology market is set to witness significant expansion, with projections indicating a market value of USD 68.4 billion by 2032, up from USD 34.1 billion in 2022. This growth, representing a strong compound annual growth rate (CAGR) of 7.2% over the forecast period, underscores the increasing importance of advanced drug delivery methods in modern healthcare.
The anticipated market growth is largely driven by the rising prevalence of chronic diseases worldwide, a trend that necessitates more effective and patient-friendly treatment options. As chronic conditions continue to burden healthcare systems globally, the demand for reliable and convenient drug delivery solutions is becoming more critical.
Explore Business Growth Strategies with In-Depth Insights: Checkout on Report Now
Oral drug delivery, in particular, is gaining traction due to its unparalleled convenience, cost-effectiveness, and enhanced patient compliance when compared to other administration methods. Patients and healthcare providers alike prefer oral delivery systems because they simplify the medication process, reduce the need for invasive procedures, and lower overall treatment costs.
The market’s expansion is further fueled by ongoing innovations in drug delivery technologies, aimed at improving therapeutic outcomes and patient experiences. These advancements are expected to make oral controlled release drug delivery systems even more effective, ensuring that they remain a preferred choice across diverse healthcare settings.
As the global healthcare landscape continues to evolve, the oral controlled release drug delivery technology market is poised to play a pivotal role in shaping the future of patient care. The projected growth underscores the market’s potential to address the increasing demands of chronic disease management, offering patients more efficient and accessible treatment options.
Market Outlook: Potential and Opportunities
The burgeoning oral controlled release drug delivery technology market presents exciting opportunities for pharmaceutical companies, research institutions, and investors. Continuous advancements in technology and the development of novel drug delivery systems are expected to further fuel market growth. Additionally, the increasing focus on personalized medicine and targeted therapies is likely to create further demand for specialized controlled release solutions.
In conclusion, the oral controlled release drug delivery technology market is poised for remarkable growth, driven by the rising burden of chronic diseases and the inherent benefits of oral drug delivery. With solid dosage forms leading the charge and advancements in technology paving the way, this market holds immense potential for stakeholders across the healthcare spectrum.
Dissolution-Controlled Release System to Remain Sought-After among Drug Release Technologies in the Market:
By drug release technology, dissolution-controlled release system will remain sought-after in the market, followed by diffusion-controlled release system. Majority of generic formulations available are in tablet dosage form and follow dissolution-controlled release mechanism. Revenues from sales of dissolution-controlled release system will surpass USD 10,000 Million in 2017. Demand for hydrodynamically-balanced drug delivery system will remain sluggish in the market.
Solid dosage forms of oral controlled release drug delivery technology are expected to remain dominant in the market, expanding at a high single-digit CAGR through 2027. Sales of semisolid/liquid/suspensions dosage form segment will register a comparatively lower CAGR than that of solid dosage forms in the market through 2027.
Enhance Your Strategy – Get Full Report Access Instantly
Key Market Players Identified in FMI’s Report Include:
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Sun Pharmaceuticals Industries Ltd
- Abbott Laboratories
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Mylan N.V.
- Sanofi
- F. Hoffman-La-Roche Ltd.
- Johnson & Johnson Services, Inc.
- Vectura Group plc.
- GlaxoSmithKline plc.
Market Taxonomy:
By Region
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- Japan
- MEA
By Drug Release System
- Diffusion Controlled Release System
- Dissolution Controlled Release System
- Osmotically Controlled Release System
- Dissolution & Diffusion Controlled Release System
- Ion Exchange Resins Controlled Release
- Hydro-dynamically Balanced Drug Delivery System
- Others
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
